"Longevity platform" now covers products that share almost nothing operationally. A $249 mail-in blood panel and a $19,500 concierge membership with an MRI suite both use the label. So does a $949 cancer blood test and a $45 finger-prick hormone kit. The category name describes a market, not a product type, which is why comparing them on marketing pages produces nothing useful.
The comparison below applies the same nine criteria to all twelve, in alphabetical order. Underneath that, the six genuine categories they fall into — because the first real decision is not which platform, but which kind of product answers the question you actually have.
The Verdict
All twelve platforms on the standard rubric
Listed alphabetically — the order carries no ranking. Annual cost is the entry tier, meaning what you pay if you never add anything. "Hidden costs" are line items reproduced by walking the actual checkout or booking flow, not taken from marketing pages.
| Platform | Category | Entry cost | Biomarkers / scope | Physician access | Main hidden cost | Public litigation | Best fit |
|---|---|---|---|---|---|---|---|
| Ezra | Imaging | $1,395–$2,395/scan | Whole-body MRI | None | Follow-up imaging after incidental findings | None publicly identified | Imaging-first screening |
| Fountain Life | Concierge | $19,500+/yr | 200+ plus MRI and CT | Bundled, in person | Travel to a clinic location | Yes — physician clinic suit (Jul 2023); source | High-net-worth, screening breadth |
| Function Health | Diagnostic | $499/yr | 100+ | Add-on consult | Advanced panels $100–$400 each | Yes — plaintiff vs Superpower (Jan 2026); source | Self-directed testers |
| Galleri | Cancer screening | ~$949/test | Blood-based MCED, 50+ cancers | Physician must order | Diagnostic workup after a positive | Yes — GRAIL in Illumina securities suit; source | Multi-cancer early detection |
| Hone Health | Hormone | ~$540–$2,640/yr | Hormone-focused | Bundled, telehealth | TRT medication billed separately | None publicly identified | TRT candidates |
| InsideTracker | Diagnostic | $249–$589/test | ~20–48 | None | Every retest is a new purchase | None publicly identified | Athletes, no membership wanted |
| Lifeforce | Physician-led | ~$1,900/yr | ~40 plus hormones | Bundled, nurse practitioner | Prescriptions billed separately | None publicly identified | Mid-tier optimization |
| Marek Health | Physician-led | $2,500–$6,000/yr | A la carte, buyer-selected | Bundled, physician | Every lab and prescription is a line item | None publicly identified | Advanced hormone and peptide users |
| Maximus | Hormone | ~$1,800–$3,600/yr | Hormone-focused | Bundled, telehealth | Labs billed separately | None publicly identified | Fertility-preserving TRT |
| Opt Health | Physician-led | ~$3,000/yr | 55+ | Bundled, physician | Prescriptions billed separately | None publicly identified | Physician-led optimization over 40 |
| Prenuvo | Imaging | $999–$2,499/scan | Whole-body MRI | None | Follow-up imaging after incidental findings | Yes — malpractice suit (Sep 2024); source | Imaging-first screening |
| Superpower | Diagnostic | $499/yr | 100+ | Add-on consult | Advanced panels $100–$400 each | Yes — defendant vs Function (Jan 2026); source | App-first testers |
The six categories, and which question each answers
Platforms within a category are close substitutes. Platforms across categories usually are not, which is why price comparisons between them mislead.
| Category | Platforms (alphabetical) | Price band | What it does | Right when |
|---|---|---|---|---|
| Diagnostic platforms | Function Health, InsideTracker, Superpower | $249–$499 | Measure broadly, explain results, stop there. No prescriptions. | You have a physician, or you are comfortable interpreting labs yourself |
| Hormone-first programs | Hone Health, Maximus | ~$540–$3,600/yr | Narrow panel, short path from test to prescription | Testosterone is the specific question you are trying to answer |
| Physician-led optimization | Lifeforce, Marek Health, Opt Health | ~$1,900–$6,000/yr | Broad panel plus a clinician who prescribes and reassesses | You expect to treat what the labs find, not just read them |
| Imaging screening | Ezra, Prenuvo | $999–$2,499/scan | Structural findings inside the imaged anatomy. One-time purchase. | Family history or a specific structural concern |
| Cancer screening (blood) | Galleri | ~$949/test | Signals across 50+ cancers, including several with no standard screen | Elevated cancer risk; layered on top of standard screening |
| Concierge | Fountain Life | $19,500+/yr | Imaging, broad biomarkers, and in-person clinician days bundled | Screening breadth matters more than cost efficiency |
The three questions that decide it
1. Do you want a test or a program? This is the single largest fork. Function Health, InsideTracker, and Superpower sell data. Fountain Life, Hone Health, Lifeforce, Marek Health, Maximus, and Opt Health sell an ongoing clinical relationship with a prescription pathway attached. Neither is better; they answer different questions. The tell is what you plan to do with an abnormal result.
2. What is the retest cadence, and what does it cost? A single biomarker snapshot ages quickly. Function Health and Superpower include two draws a year. InsideTracker sells each test separately. Marek Health retests every 8–12 weeks during active titration. Concierge programs run quarterly. Multiply the retest cost by your intended frequency before comparing headline prices — this is where the real annual difference lives.
3. Who reads the results with you? Clinician access is bundled at Fountain Life, Hone Health, Lifeforce, Marek Health, Maximus, and Opt Health. It is a paid add-on at Function Health and Superpower, and absent by design at InsideTracker, where interpretation is algorithmic. If you already have a physician who will read a broad panel with you, the diagnostic platforms are the more efficient purchase.
What "at-home blood test" actually covers
The phrase covers three different products, and the differences decide both price and reliability. A self-collect kit ships a lancet and either a filter card or a microtube; you draw your own capillary sample and mail it. A mobile phlebotomy panel sends a phlebotomist to your address for a standard venous draw — the sample is identical to one taken in a clinic. A lab-requisition platform sells the panel online and sends you to a partner draw site, which is not an at-home test at all despite being marketed alongside them.
Most of the twelve platforms above use the second or third route, which is why their results are directly comparable to a clinic panel. Self-collect kits are cheaper and are the format where accuracy varies by marker: vitamin D, HbA1c and hs-CRP survive capillary collection well, while potassium and full blood counts do not. At-home blood test accuracy covers which markers hold up and the collection error behind most bad results.
The other split is one-time versus subscription. A single panel with no ongoing commitment runs roughly $150–$400 self-ordered; the subscription platforms bundle two draws a year plus an app and clinician access into an annual fee. The subscription is the better purchase only if you will actually use the second draw and the interpretation layer — a baseline you never repeat is cheaper bought once.
What none of these platforms do
- Replace primary care. None manage acute illness, chronic disease outside their scope, or emergencies.
- Diagnose from a panel alone. An abnormal marker is a starting point for a workup, not a diagnosis.
- Guarantee insurance coverage of what they find. A finding on an elective screen can trigger a workup your insurer treats differently than one prompted by symptoms.
- Substitute for age-based screening. Colonoscopy, mammography, cervical screening and lung CT remain the standard of care regardless of what any platform reports.
Comparison deep dives
- Function Health vs Superpower
- Hone Health vs Marek Health
- InsideTracker vs Function Health
- Lifeforce vs Function Health
- Maximus vs Hone Health
- Opt Health vs Fountain Life
- Opt Health vs Function Health
- Opt Health vs Hone Health
- Opt Health vs Lifeforce
- Opt Health vs Marek Health
- Opt Health vs Maximus
- Opt Health vs Superpower
- Prenuvo vs Ezra
Alternatives roundups
Category explainers
- At-home blood test accuracy — which markers survive self-collection and which do not
- Longevity clinic cost — real price bands and the six fees outside the membership
- Full body MRI scan — what a whole-body protocol detects, what it under-reads, and what it costs
- Cancer screening blood test accuracy: what sensitivity and specificity mean when the result is yours
- Best multi-cancer blood test: Galleri, Cancerguard, Trucheck and OneTest on evidence
- Colon cancer blood test vs colonoscopy: what each one finds and what only one prevents
- What is a longevity clinic — the four models, credentials, and how to vet one
Related
- Doctor-led programs compared
- Biomarker guides — what the panels actually measure
- Guides by audience
- How we review
Frequently Asked Questions
What is the difference between a diagnostic platform and a physician-led program?
A diagnostic platform measures and explains. It hands you a panel, writes commentary on each result, and recommends you see a doctor if something is out of range — it does not become that doctor. A physician-led program includes the clinician, a prescription pathway, and a reassessment cadence in the price. The practical test: if a marker comes back abnormal, does the platform treat it or refer it? Function Health, InsideTracker, and Superpower refer. Fountain Life, Hone Health, Lifeforce, Marek Health, Maximus, and Opt Health treat.
Why do the prices vary so much for what looks like the same thing?
Because the biomarker count is the least expensive part of the product. Running 100 markers costs a lab very little more than running 40. What drives price is clinician time, reassessment frequency, prescription management, and imaging. A $499 platform and a $3,000 platform can run overlapping panels — the difference is whether a physician reads them with you every quarter and can prescribe off the result.
Is a bigger biomarker panel better?
Not automatically, and it is actively worse as a first purchase. Reference ranges are built as the central 95% of a healthy population, which means roughly 1 in 20 markers flags in a healthy person by arithmetic alone. A 100-marker panel typically returns 10–25 flagged values on a naive baseline, most of which are statistical noise. Without someone to sort signal from noise, breadth produces anxiety rather than information.
Do any of these take insurance?
Essentially none for the membership or the screening itself. All of the platforms compared here are cash-pay. Many are HSA/FSA eligible, which is the closest thing to a discount available. The exception worth planning for is downstream: if imaging or a cancer screen finds something, the diagnostic workup that follows is ordered by your own physician and may be insurance-covered — but coverage of an elective-screening follow-up is not guaranteed.
How often should I retest?
It depends on what you are changing. Markers that respond in weeks — fasting insulin, hsCRP, lipids after a diet change — are meaningfully retestable at 6–12 weeks. HbA1c reflects roughly the previous three months, so retesting it sooner measures the previous quarter, not the change. Hormone protocols under active titration typically retest at 6–12 weeks. Once stable, most markers are annual. A program retesting quarterly costs several times one retesting annually for the same panel, so the cadence is a real cost driver.
Can I combine platforms?
You can, and it is usually redundant. Two diagnostic platforms measure largely the same markers. The combinations that make sense are across categories rather than within one: a broad diagnostic panel plus an imaging scan, or a physician-led program plus a one-time cancer screen. Stacking two products in the same category means paying twice for overlapping data.
What should I buy first?
For most people the answer is nothing yet. Sleep duration, resistance training, protein intake, alcohol reduction, and blood pressure control are free and account for most of the achievable benefit for anyone who has not addressed them. Testing earns its cost once those are in place, when symptoms persist despite them, or when you need a baseline before starting something with real risk such as hormone therapy.